Keywords: Multiple sclerosis, Neurologists, Serono, Merck KGaA, Movectro, Novartis, Gilenia, Extavis, Acorda, Ampyra
Neurologists eagerly await new oral treatment options for MS, such as EMD Serono's Movectro and Novartis' Gilenia
Article | 27 April 2010
A new study, based on feedback gathered in an on-line survey completed by 100 neurologists in March this year, found that, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
